Suppr超能文献

多肽-药物偶联物用于癌症治疗。

Polypeptides-Drug Conjugates for Anticancer Therapy.

机构信息

Key Laboratory of Polymer Ecomaterials, Jilin Biomedical Polymers Engineering Laboratory, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P. R. China.

School of Materials Science and Engineering, Changchun University of Science and Technology, Changchun, 130022, P. R. China.

出版信息

Adv Healthc Mater. 2021 Jun;10(11):e2001974. doi: 10.1002/adhm.202001974. Epub 2021 Apr 30.

Abstract

Polypeptides are an important class of biodegradable polymers that have been widely used in drug delivery field. Owing to the controllable synthesis and robust side chain-functionalization ability, polypeptides have long been ideal candidates for conjugation with anticancer drugs. The chemical conjugation of anticancer drugs with polypeptides, termed polypeptides-drug conjugates, has demonstrated several advantages in improving pharmacokinetics, enhancing drug targeting, and controlling drug release, thereby leading to enhanced therapeutic outcomes with reduced side toxicities. This review focuses on the recent advances in the design and preparation of polypeptides-drug conjugates for enhanced anticancer therapy. Strategies for conjugation of different types of drugs, including small-molecule chemotherapeutic drugs, proteins, vascular disrupting agents, and gas molecules, onto polypeptides backbone are summarized. Finally, the challenges and future perspectives on the development of innovative polypeptides-drug conjugates for clinical cancer treatment are also presented.

摘要

多肽是一类重要的可生物降解聚合物,已广泛应用于药物传递领域。由于可控合成和强大的侧链功能化能力,多肽一直是与抗癌药物结合的理想候选物。将抗癌药物与多肽进行化学偶联,称为多肽-药物偶联物,在改善药代动力学、增强药物靶向性和控制药物释放方面具有多种优势,从而提高治疗效果,降低毒副作用。本文综述了设计和制备用于增强抗癌治疗的多肽-药物偶联物的最新进展。总结了将不同类型的药物(包括小分子化疗药物、蛋白质、血管破坏剂和气体分子)偶联到多肽主链上的策略。最后,还提出了开发用于临床癌症治疗的创新型多肽-药物偶联物的挑战和未来展望。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验